|
[1]
|
Sharma, A. and Hariharan, S. (2019) Octreotide Delaying the Progression of Recurrent IgA Nephropathy after Kidney Transplantation. Transplant Direct, 6, e518. [Google Scholar] [CrossRef]
|
|
[2]
|
Zand, L., Can-etta, P., Lafayette, R., et al. (2019) An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. Kidney International Reports, 5, 58-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
白亚君, 杜艳彬, 袁心柱, 等. 大黄酚介导TLR4/NF-κB通路对IgA肾病大鼠肾损伤和免疫反应的调控作用[J]. 四川大学学报(医学版), 2019, 50(6): 840-846.
|
|
[4]
|
傅槟槟, 万建新. IgA肾病肾血管病变与临床病理之间的关系[J]. 中国当代医药, 2009, 16(24): 75-77.
|
|
[5]
|
关欣, 郑红光. IgA肾病肾血管病变危险因素的非条件logsitick回归分析[J]. 华西医学, 2011, 26(8): 1121-1124.
|
|
[6]
|
中华医学会儿科学分会肾脏学组. 原发性IgA肾病诊治循证指南(2016) [J]. 中华儿科杂志, 2017, 55(9): 643-646.
|
|
[7]
|
Lee, S.M.K., Rao, V.M., Franklin, W.A., et al. (1982) IgA Nephropathy: Morphologic Predictors of Progressive Renal Dis-ease. Human Pathology, 13, 314-322. [Google Scholar] [CrossRef]
|
|
[8]
|
容丽萍, 姜梦婕, 莫樱, 等. Katafuchi半定量评分系统和IgA肾病牛津病理分型在儿童IgA肾病的临床应用[J]. 发育医学电子杂志, 2015(3): 145-151.
|
|
[9]
|
中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会中国医师协会高血压专业委员会, 等. 中国高血压防治指南(2018年修订版) [J]. 中国心血管杂志, 2019, 24(1): 24-56.
|
|
[10]
|
孙明姝, 母义明, 赵家军, 等. 中国临床指南现状分析及《中国高尿酸血症与痛风诊治指南(2018)》制定介绍[J]. 中华内分泌代谢杂志, 2019, 35(3): 181-184.
|
|
[11]
|
李想, 张倩, 聂春迎, 等. 与原发性IgA肾病患者肾间质纤维化程度相关的因素分析[J]. 山东医药, 2019, 59(30): 78-80.
|
|
[12]
|
Zhang, H., Jia, J., Cheng, J., et al. (2012) 1H NMR-Based Metabonomics Study on Serum of Renal Interstitial Fibrosis Rats Induced By Unilateral Ureteral Obstruction. Molecular BioSystems, 8, 595-601. [Google Scholar] [CrossRef]
|
|
[13]
|
Feiner, H.D., Cabili, S., Baldwin, D.S., Schacht, R.G. and Gallo, G.R. (1982) Intrarenal Vascular Sclerosis in IgA Nephropathy. Clinical Nephrology, 18, 183-192.
|
|
[14]
|
刘泽洲, 苏可, 杨定平, 等. IgA肾病伴高血压患者临床病理改变特征及预后分析[J]. 中华肾脏病杂志, 2019, 35(9): 648-654.
|
|
[15]
|
汪晶华, 杨洁, 刘宇, 等. 伴有高血压的IgA肾病临床表现、病理特点及高血压发生的影响因素分析[J]. 解放军医药杂志, 2016, 28(10): 73-76.
|
|
[16]
|
李思瓯, 尹昌浩, 张忠敏. 益肾汤配合西药治疗IgA肾病伴高血压36例[J]. 世界中医药, 2013, 8(5): 528-529.
|
|
[17]
|
吕天洋, 张静, 贾红彦, 等. 原发性IgA肾病并发血尿酸升高患者影响因素分析[J]. 中国实验诊断学, 2019, 23(9): 1536-1537.
|
|
[18]
|
张永哲, 刘大军. IgA肾病合并高尿酸血症患者临床及病理特点分析[J]. 中国中西医结合肾病杂志, 2018, 19(10): 911-913.
|
|
[19]
|
张永哲, 刘大军. IgA肾病合并高尿酸血症患者临床及病理特点分析[J]. 中西医结合心脑血管病杂志, 2018, 19(13): 911-913.
|
|
[20]
|
张函, 章晓燕, 卢泽军, 等. 吸烟对IgA肾病(IgAN)患者肾功能和肾小管间质及血管病变的影响[J]. 复旦学报(医学版), 2014, 41(3): 315-320.
|
|
[21]
|
Cattran, D.C., Coppo, R., Cook, H.T., et al. (2009) The Oxford Classification of IgA Nephropathy: Ra-tionale, Clinicopathological Correlations, and Classification. Kidney International, 76, 534-545. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Tang, S.C., Tang, A.W., Wong, S.S., et al. (2010) Long-Term Study of Mycophenolate Mofetil Treatment in IgA Nephropathy. Kidney International, 77, 543-549. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Moorhead, J.F., Chan, M.K., El-Nahas, M., et al. (1982) Lipid Ne-phrotoxicity in Chronic Progressive Glomerular and Tubulo-Interstitial Disease. The Lancet, 2, 1309-1311. [Google Scholar] [CrossRef]
|
|
[24]
|
Tang, Z.Y., Lu, B., Hatch, E., et al. (2009) C3a Mediates Ep-ithelial-to-Mesenchymal Transition in Proteinuric Nephropathy. Journal of the American Society of Nephrology, 20, 593-603. [Google Scholar] [CrossRef]
|
|
[25]
|
Rifai, A. (2007) IgA Nephropathy: Immune Mechanisms beyond IgA Mesangial Deposition. Kidney International, 72, 239-241. [Google Scholar] [CrossRef] [PubMed]
|